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Abstract
A method of care of patients with locally-advanced breast cancer consisting of using regional selective intraar-
terial chemotherapy in the schedule of the complex (palliative) treatment is presented. Results of treatment showed an 
advantage in comparison with the application of traditional methods of the breast cancer treatment. The methodology 
on intra-arterial introduction of chemotherapeutic agents developed at Donetsk Regional Antitumoral Center and Uni-
versity clinic of Odessa showed its undisputable contribution into development of modern oncology through decrease of 
primary tumoral locus, transition from inoperable state into the state at which it is possible to perform the radical volume 
of surgical interference to patient. The special attention is paid to development of new methods of treating BC patients 
(regional forms of disease) with unfavorable factors for forecast of tumor growth.
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1. Introduction
The urgency of developing the new methods of treatment for patients with breast cancer (BC) 
is undoubtful now. Unfortunately statistics shows a steady increase in the incidence of breast cancer 
in the past 20 years, with no tendency to stabilization [1, 2]. Morbidity (72.8 cases per 100,000 female 
population in 2014) and mortality (32.0 %) in Ukraine is approaching the level of the European Union.
Particular attention is paid to the development of new methods of treatment of breast cancer 
patients with locally advanced forms of the disease or the presence of significant comorbidities 
which does not allow perform the radical surgery.
2. The purpose of the work
To improve the immediate and long-term results of treatment of patients with locally-ad-
vanced forms of BC, to improve their life quality.
3. Materials and methods
The present study was based on the data of 136 patients with locally-advanced and metastat-
ic forms of BC, with the stages T4N0-2M0-1 treated in 1997–2013.
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During the research for an adequate analysis of the results of treatment by the technique under 
study there were formed two groups of patients. The first study group included 92 patients who had 
complex treatment program: two or three cycles of selective intra-arterial polychemotherapy (PCT) with 
an interval of 21 days, evaluation of the effect, the interval, radiation therapy (RT) of the breast and areas 
of the regional lymph outflow in the static mode SFD – 2–2.5 Gy, CFD – 40 Gy, the interval, evaluation 
of the effect, the second phase of RT with SFD 2–2.5 Gy with elevation of the dose up to – CFD 60 Gy 
against the background of the third course of PCT, evaluation of the effect, the interval of three weeks, 
the fourth course of palliative chemotherapy in adequate functioning of the catheter. Catheterization of 
the internal thoracic artery was made through the upper epigastricone (a patent № 29318 of Ukraine of 
01.07.2000, a patent № 2169014 of the Russian Federation of 20.06.2001). Mastectomy in the patients of 
the group under investigation was performed only at presence of bleeding from the tumor (16 of 92 pa-
tients at different stages of treatment). When performing mastectomy some of these patients were cathe-
terized the perforating branch of the internal thoracic artery (ITA) – for further IAPHT – worked out in 
Donetsk regional antitumor center by the original method (a patent № 29318 of Ukraine of 01.07.2000). 
Courses of intraarterial PCT were given by the scheme CMF, CAF or CAMF. The number of courses is 
determined based on the evaluation of the effectiveness of treatment, general condition of the patients 
and presence and severity of local and systemic complications. Usually 2–3 cycles were sufficient to 
achieve the effect of neoadjuvant mode. If no effect was observed, the scheme of PCT included anthra-
cyclines (1–2 cycles) [3–5].
The control group comprised 44 patients who were given 4–6 cycles of systemic PCT 
schemes of CMF, CAF or CAMF at the first stage of treatment, then mastectomy was performed. 
Further on the patients consulted a radiologist to decide on the appropriateness of radiotherapy.
At examination during primary visit 7 (7.6±3.4 %) patients of the investigated group were 
revealed distant metastases.
In this case the patients in this group were most frequently detected bone metastases as it 
was noted in 4 (4.3±2.6 %) cases there were detected liver metastases, metastatic mediastinal and 
contralateral pleural effusion – 1 (1.08±1.08 %) cases respectively with the same frequency. Pulmo-
nary metastases in patients of the group under investigation were not marked [6–10].
Histological examination of trephine biopsy materials in the investigated group of the 
patients revealed tumors of the following morphological structure: noninfiltrating: intraductal 
cancer – 1 (1.08±1.08 %); lobular carcinoma – 1 (1.08±1.08 %); infiltrating: infiltrating ductal carci-
noma – 49 (53.3±5.8 %); infiltrating ductal carcinoma with a predominance of intraductal compo-
nent 9 (9.8±3.8 %); infiltrating lobular carcinoma 30 (32.6±5.3 %); medullar cancer 1 (1.08±1.08 %); 
papillary carcinoma 1 (1.08±1.08 %)
In 59 (64.1±5.5 %) patients of the investigated group there was revealed overexpression of 
estrogen and progesterone receptors (ER±PR±), 5 (5.4±2.9 %) were revealed to have overexpres-
sion of estrogen receptors at the absence of expression of progesterone receptors (ER±PR–) which 
was an indication for the use of two-way tubovariectomy or releasing hormone agonists in the pa-
tients in pre-menopause. On the basis of immunohistochemical data the postmenopausal patients 
were administered corresponding conservative hormonal therapy. In 20 (21.7±5.1 %) patients of the 
investigated group the tumor did not express estrogen and progesterone receptors (ER–PR–), and 
3 (3.2±2.3 %) patients showed no expression of estrogen receptors at the presence of the proges-
terone receptor expression (ER–PR±). There were found no statistically significant differences in 
the immunnohistochemical status of the patients in the control group. The immunnohistochemical 
status of the tumor has not been studied in 5 patients of the investigated group.
At examination during the primary visit 5 (11.4±4.8 %) patients in the control group were 
revealed distant metastases.
Bone metastases were the most frequently reported in the patients of the control group as 
well as in the patients of the group under study; it was noted in 3 (6.8±3.8 %) cases. Equally com-
mon metastases were encountered in the liver and lungs – 1 (2.3±2.3 %) cases respectively. Meta-
static pleural effusion and mediastinal involvement has been identified in the patients of this group 
during the primary visit. In case of metastatic affections of the bones bisphosphonates were added 
in the scheme of complex treatment of patients in the control and investigated groups.
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In the control group of patients histological identification of tumors were represented by the 
following morphological variants: noninfiltrative: lobular carcinoma – 1 (2.3±2.3 %); infiltrating: in-
filtrating ductal carcinoma – 25 (56.8±7.5 %); infiltrating ductal carcinoma with a predominance of 
intraductal component 7 (15.9±5.5 %); infiltrative lobular carcinoma – 10 (22.7±6.3 %); medullar 
cancer 1 (2.3±2.3 %). Statistically significant differences in the frequency of different morphologi-
cal variants between patients of the control and investigated groups were not found (p=0.87).
Also there was no statistically significant difference in the distribution of staging in category 
N patients in the controls and the group under the investigation (p=0.06).
The analysis of the age, prevalence of tumor, presence of comorbidity of the patients showed 
that they were homogeneous in the control and investigated groups.
All patients were informed in detail with the objectives of the study, the programs of thera-
peutic and diagnostic procedures and gave their written informed consent for this type of treatment.
In accordance with the protocol of this study, the scheme of complex treatment of all patients 
included radiation therapy that was given at the radiological department of Donetsk regional anti-
tumor center. Irradiation of the primary lesion and regional areas was performed by gamma – ther-
apeutic devices “Rokus” and “Agat” in the classical modes of dose fractionation.
In carrying out small fraction radiotherapy single focal dose to the mammary gland was 
2–2.5 Gray, to the zones of the regional lymph outflow – 2 Gray. The cumulative tumor dose to the 
breast was 47–60 Grey, zones of the regional lymph outflow – 47–60 Gray [11–14].
Hormone therapy was given in accordance with modern views and approaches to this prob-
lem. Pharmacological or surgical ablation was performed in the patients with preserved menstrual 
function and presence of the steroid hormone receptors in the tumor after which the anti-estrogen 
drugs were administered for 2–3 years, followed by administration of aromatase inhibitors or anti-
estrogens extension up to 5 years [15–20]. Anti-estrogens or aromatase inhibitors were prescribed 
for all patients in postmenopause that had not been studied hormonal status of the tumor or the hor-
monal status of the tumor was positive. At the absence of steroid hormone receptors tumor hormone 
therapy was not given [21, 22].
4. Results and discussion.
Immediate results of palliative treatment of patients
Evaluation of the effect of the treatment was made in the period after neoadjuvant chemotherapy.
Traditionally to assess the objective effect of chemotherapy there were used the well-known 
criteria of the WHO Expert Committee. The evaluation of the tumor size and metastases was used 
as a derivative of the two largest perpendicular sizes. It should be noted that the instrumental tests 
were made in the same hospital (DRATC) in compliance with the principles of continuity (one 
apparatus and the same specialists). For linear measurements of breast tumors there was used a 
medical caliper of McGhan company with divisions of 0.1 mm.
In the course of evaluating the effectiveness of the method in therapy of solid tumors the 
scale RECIST (Response Evaluation Criteria in Solid Tumors) was used. In all cases tumors were 
assessed as measurable. The maximum size of all lesions was determined, total size before treat-
ment was considered as the baseline and compared with that after treatment.
In evaluating the therapeutic effect there were taken into consideration dynamics of the ob-
jective state of patients and results of clinical and laboratory examinations, and dynamic trephine 
biopsy was made (evaluation of tumor pathomorphism after PCT)
Long-term efficacy of the treatment
The clinical course of the disease and long-term results of treatment were assessed by the 
following parameters:
– life expectancy without recurrences and new metastases;
– frequency of lymphatic and hematogenous metastasis;
– corrected five-year survival rate.
These indices were calculated in all investigated contingent of the patients and separately for 
the control and investigated groups depending on the variants of palliative treatment.
Calculation of long-term results was made from the beginning of treatment.
Original Research Article:
full paper
(2016), «EUREKA: Health Sciences»
Number 1 
48
Evaluation of the effectiveness of treatment of the investigated patients revealed: the total ef-
fect was observed in 6 (6.5±3.1 %) patients, partial response – in 59 (64.1±5.5 %) women, stabilization 
of the process was detected in 21 (22 8±4.5 %) cases, the disease advance – in 6 (6.5±3.1 %) cases.
In the control group of patients the following effectiveness of the palliative treatment was re-
vealed: the total effect was detected in 3 (6.8±3.8 %) patients, partial response – in 19 (43.2±7.5 %) 
cases, stabilization of the process was found in 10 (22.7±6.3 %) patients, the disease advance was 
observed in 12 (27.3±6.7 %) patients. Differences in distributions of effectiveness evaluation of 
treatment for the patients in the control and investigated groups by the RECIST scale is statistically 
significant (p=0.02) (Table 1).
Table 1
The effectiveness of treatment of the patients






Total 6 6.5±3.1 3 6.8±3.8
Partial 59 64.1±5.5 19 43.2±7.5
Stabilization 21 22.8±4.5 10 22.7±6.3
Advance 6 6.5±3.1 12 27.3±6.7
Assessing the risk ratio one can conclude that the risk of the disease advance for the patients 
of the investigated group compared with the controls decreases in RR=3.4 (CI 1.4–8.4) times (the 
difference is statistically significant, p=0.01).
The effect of the treatment was evaluated by mammography.
Long-term results of palliative treatment of the patients
During the follow-up the investigated patients were revealed the following variants 
for advance of the disease after treatment: totally the advance of the disease was observed in 
28 (30.4±5.6 %) patients, four of them had metastatic pleuritis, the average interval before contin-
uation of the disease was 5.1±0.8 months. Pulmonary metastases were detected in the 1st patient in 
13.5 months. Liver metastases were detected in 1 patient at the control examination in 31.5 months. 
New skeletal lesions were diagnosed in 10 (10.8±3.9 %) patients on an average in 10.2±3.3 months. 
Intradermal metastases were detected in 2 patients; the average interval was 13.5 months. Contin-
ued growth of the tumor was found in 7 (7.6±3.4 %) patients; on an average in 10.2±3.4 months. A 
supraclavicular lymph node metastatic lesion was found in 1 case in 39 months. Brain metastases 
were detected in 1 patient after 6 months after completion of treatment. Combination of pleurisy 
and metastatic liver metastases was diagnosed in 1 case in 13 months after the end of chemoradi-
ation and surgery.
The patients in the control group were obtained the following results during the dynamic 
follow-up: 21 (47.7±7.5 %) patients showed a continuation of the disease. 2 patients were diagnosed 
metastatic pleurisy, the average interval was 21 months. Pulmonary metastases were detected in 
one patient in 18 months. Bone metastases were diagnosed in 4 (9.1±4.3 %) patients on an average 
in 16.1±4.9 months. Intradermal metastases were detected in 6 (13.6±5.2 %) patients on an average 
in the interval of 15.6±4.5 months. Continued growth of the tumor was found in 4 (9.1±4.3 %) patients, 
on an average in 24.3±11.5 months. Brain metastases were detected in 1 patient in 2.5 months 
after completion of treatment. Supraclavicular lymph node metastatic lesions were detected in 
3 (6.8±3.8 %) cases in an interval of 12.9±5.0 months.
All patients diagnosed with the disease continuation received palliative symptomatic treatment.
Consideration of cases of the disease continuation revealed the following results: in the con-
trol group a minimum period of metastasis was 4.6 months, maximum – 23.2 months; while in the 
investigated group of patients the minimum and maximum period of metastasis made 4.7 months 
and 54.1 months, correspondingly. The average time till metastases (median rate) in the control 
group was 7.9±2.4 months, whereas in the instigated one it was 14.5±3.5 months (the difference is 
not statistically significant, p>0.05).
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Median survival rate for the investigated patients was 35.5 months while it was 13.9 months 
for the patients in the control group.
5. Discussion of the results
The comparison of the survival curves for both groups of the patients showed a statistical-
ly significant difference (p<0.001 at using log-rank test with Yates correction). It was found that 
the patients who achieved a complete or partial effect of treatment by the RECIST scale live lon-
ger after selective intra-arterial chemotherapy. Complete or partial response by the RECIST scale 
(p=0.02) was recorded more often in the patients in the investigated group that was resulted in their 
best survival rates.
All patients diagnosed with a continuation of the disease received palliative chemo- and 
hormone treatment. The average life expectancy in these patients was 11.4 months. The greatest 
number of patients with a continuation of the disease (26 women) died within 12 months after 
the end of the palliative treatment. The next peak registration of deaths is observed in the third 
year of the follow-up.
The average life expectancy of the patients of the investigated group was 50.52±14.4 months, 
significantly exceeding the statistical data of domestic and foreign authors. Indices of total 3-year 
survival rate of the patients of the investigated group made up 77.7 % ±12.1 months, and 5-year – 
63.0±14.5 months.
In the control group index of 3- and 5-year survival rates were significantly lower – 62.4±19.3 % 
and 44.7 % ±22.4 months respectively.
6. Conclusion 
Results of complex treatment of locally- advanced breast cancer by the developed technique 
using selective intra-arterial chemotherapy in the pool of the internal thoracic artery in combina-
tion with radiation and hormonal therapy exceed the results of standard treatment programs for 
patients with the locally-advanced forms of breast cancer with the performance of mastectomy and 
systemic chemotherapy. The technique developed by the authors can be recommended for wide use 
in such patients.
References
[1] Aksel, E. M. (2006). Malignant neoplasm of the breast: state of oncologic care, morbid-
ity and mortality. Mammalogy, 1, 9–13.
[2] Shalіmova, S. O. (Ed.) (2012). Cancer in Ukraine. Morbidity, indices of activity of the 
oncologic service. Bulletin of the national Cancer register of Ukraine. Kiev, 13, 51. 
[3] Bondar, G. V., Sedakov, І. E., Shlopov, V. G. (2006). Primary breast cancer. Donetsk: 
Kashtan, 348.
[4] Tsunoda, Y., Suzuki, K., Sakamoto, M. A. et. al (2009). Evaluation of fluorouracil-re-
lated genes in breast cancer to predict the effect of adjuvant therapy with CMF. Gan To Kagaku 
Ryoho., 36 (1), 51–55.
[5] Chen, A. M., Meric-Bernstam, F., Hunt, K. K. et. al (2004). Conservation After Neo-
adjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience. Journal of Clinical On-
cology, 22, 2303–2312.
[6] Cals, L., Nouyrigat, P., Tchiknavorian, X. et. al (2004). Neoadjuvant weekly paclitaxel 
and epirubicin in patients with inflammatory and T4 breast cancer (IBC-T4BC): Results of a VAR 
Cancer Society trial. Proc Am Soc Oncol., 23.
[7] Mikeljevic, J. S., Haward, R., Johnston, C., Crellin, A., Dodwell, D., Jones, A. et. 
al (2004). Trends in postoperative radiotherapy delay and the effect on survival in breast can-
cer patients treated with conservation surgery. British Journal of Cancer, 90 (7), 1343–1348. 
doi: 10.1038/sj.bjc.6601693
[8] Deniaud-Alexandre, E., Lauratet, B., Lefranc, J. P., Genestie, C., Lerouge, D., 
Moureau-Zabotto, L., Touboul, E. (2004). Isolate local failure after breast-conserving treatment for 
early breast cancer, about 57 cases. Cancer Radiother, 8 (2), 95–107. 
Original Research Article:
full paper
(2016), «EUREKA: Health Sciences»
Number 1 
50
[9] Kuerer, H. M., Julian, T. B., Strom, E. A., Lyerly, H. K., Giuliano, A. E., Mamounas, E. P., 
Vicini, F. A. (2004). Accelerated Partial Breast Irradiation After Conservative Surgery for Breast 
Cancer. Annals of Surgery, 239 (3), 338–351. doi: 10.1097/01.sla.0000114219.71899.13
[10] He, J., Wang, X., Guan, H., Chen, W., Wang, M., Wu, H. et. al (2011). Clinical efficacy 
of local targeted chemotherapy for triple-negative breast cancer. Radiology and Oncology, 45 (2). 
doi: 10.2478/v10019-011-0014-7
[11] Pacetti, P., Mambrini, A., Paolucci, R. et. al (2006). Intra-arterial chemotherapy: A safe 
treatment for elderly patients with locally advanced breast cancer. In Vivo, 20, 761–764.
[12] Takizawa, K., Shimamoto, H., Ogawa, Y., Yoshimatsu, M., Yagihashi, K., Nakaji-
ma, Y., Kitanosono, T. (2009). Development of a New Subclavian Arterial Infusion Chemotherapy 
Method for Locally or Recurrent Advanced Breast Cancer Using an Implanted Catheter–Port Sys-
tem After Redistribution of Arterial Tumor Supply. CardioVascular and Interventional Radiology, 
32 (5), 1059–1066. doi: 10.1007/s00270-009-9510-1
[13] Bondar’, G. V., Sedakov, I. E., Shlopov, V. G. et. al (2006). Vnutriarterial’naya polikhi-
mioterapiya u bol’nykh rakom molochnoi zhelezy. Onkologiya, 8 (2), 116–120.
[14] Tarazov, P. G., Korytova, L. I., Shachinov, E. G. (2011). Vnutriarterial’naya terapiya 
raka molochnoi zhelezy. Voprosy onkologii, 57 (1), 126–131.
[15] Kitagawa, K., Yamakado, K., Nakatsuka, A., Tanaka, N., Matsumura, K., Takeda, K., 
Kawarada, Y. (2002). Preoperative transcatheter arterial infusion chemotherapy for locally ad-
vanced breast cancer (stage IIIb) for down-staging and increase of resectability. European Journal 
of Radiology, 43 (1), 31–36. doi: 10.1016/s0720-048x(01)00417-x
[16] Pacetti, P., Mambrini, A., Paolucci, R. et. al (2006). Intra-arterial chemotherapy: A safe 
treatment for elderly patients with locally advanced breast cancer. In Vivo, 20, 761–764.
[17] Umarova, K. R., Arybzhanov, D. T., Yakubova, M. B. (2008). Rezul’taty vnutriarteri-
al’noi khimioterapii raka molochnoi zhelezy. Tomsk, 130–131.
[18] Kim, T., Lau, J., Erban, J. (2006). Lack of Uniform Diagnostic Criteria for Inflamma-
tory Breast Cancer Limits Interpretation of Treatment Outcomes: A Systematic Review. Clinical 
Breast Cancer, 7 (5), 386–395. doi: 10.3816/cbc.2006.n.055
[19] Tabei, T., Sato, K., Inoue, K., Nakano, S., Kai, T., Futsuhara, K. et. al (2006). Multi-
center, prospective study of radiotherapy without surgery after AC followed by weekly paclitaxel 
for patients with inflammatory breast cancer: SBCCSG-04 study. Journal of Clinical Oncology, 
24 (18S), 10783.
[20] Veyret, C., Levy, C., Chollet, P., Merrouche, Y., Roche, H., Kerbrat, P. et. al (2006). 
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemother-
apy. Cancer, 107 (11), 2535–2544. doi: 10.1002/cncr.22227
[21] Yang, W. T., Le-Petross, H. T., Macapinlac, H., Carkaci, S., Gonzalez-Angu-
lo, A. M., Dawood, S. et. al (2007). Inflammatory breast cancer: PET/CT, MRI, mammogra-
phy, and sonography findings. Breast Cancer Research and Treatment, 109 (3), 417–426. doi: 
10.1007/s10549-007-9671-z
[22] Rousseau, C., Devillers, A., Sagan, C., Ferrer, L., Bridji, B., Campion, L. et. al (2006). 
Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by 
[18F]Fluorodeoxyglucose Positron Emission Tomography. Journal of Clinical Oncology, 24 (34), 
5366–5372. doi: 10.1200/jco.2006.05.7406
